renal tubular acidosis or severe infections of the urinary tract). Cardiac Disorders -cardiac failure congestive. The patient experienced coma, diplopia, and agitation, but subsequently recovered.

Memantine oral tablet is a prescription medication used to treat moderate to severe dementia caused by Alzheimer’s disease. For patients randomized to memantine hydrochloride, treatment was initiated at 5 mg once daily and increased weekly by 5 mg/day in divided doses to a dose of 20 mg/day (10 mg twice a day). In the clinical studies of memantine hydrochloride the mean age of patients was approximately 76; over 90% of patients were 65 years and older, 60% were 75 years and older, and 12% were at or above 85 years of age. Because the patients entered were a mixture of Alzheimer’s disease and vascular dementia, an attempt was made to distinguish the two groups and all patients were later designated as having either vascular dementia or Alzheimer’s disease, based on their scores on the Hachinski Ischemic Scale at study entry.

The curves show that both patients assigned to memantine hydrochloride/donepezil and placebo/donepezil have a wide range of responses and generally show deterioration, but that the memantine hydrochloride/donepezil group is more likely to show a smaller decline or an improvement.Figure 7 shows the time course for the change from baseline in SIB score for the two treatment groups over the 24 weeks of the study. A statistically significant treatment difference at 12 weeks that favored memantine hydrochloride over placebo was seen on both primary efficacy measures. Only about 50% of the patients had computerized tomography of the brain. Cerner Multum, Inc. "Australian Product Information." These reactions include:Blood and Lymphatic System Disorders - agranulocytosis, leukopenia (including neutropenia), pancytopenia, thrombocytopenia, thrombotic thrombocytopenic purpura.Renal and Urinary Disorders - acute renal failure (including increased creatinine and renal insufficiency).The clearance of memantine was reduced by about 80% under alkaline urine conditions at pH 8.

Renal clearance involves active tubular secretion moderated by pH dependent tubular reabsorption.Following multiple dose administration of memantine hydrochloride 20 mg daily, females had about 45% higher exposure than males, but there was no difference in exposure when body weight was taken into account.The pharmacokinetics of memantine hydrochloride in young and elderly subjects are similar.Memantine pharmacokinetics were evaluated following single oral administration of 20 mg memantine HCl in 8 subjects with mild renal impairment (creatinine clearance, CLNo dosage adjustment is recommended for patients with mild and moderate renal impairment. Therefore, alterations of urine pH towards the alkaline condition may lead to an accumulation of the drug with a possible increase in adverse effects. Memantine, which is no more effective, has dopaminergic and atropinic effects but is not a cholinesterase inhibitor. There may be new information. The next dose should be taken as scheduled. Diarrhea 5. Using an LOCF analysis, memantine hydrochloride treatment was statistically significantly superior to placebo.Figure 4 shows the cumulative percentages of patients from each treatment group who had attained at least the measure of change in SIB score shown on the X axis. Forest Pharmaceuticals, St. Louis, MO. Study Outcome Measures: In each U.S. study, the effectiveness of memantine hydrochloride was determined using both an instrument designed to evaluate overall function through caregiver-related assessment, and an instrument that measures cognition.